Chemotherapy-Related Hospitalization Among Community Cancer Center Patients

被引:62
作者
Hassett, Michael J. [1 ]
Rao, Sowmya R. [2 ]
Brozovic, Suzana [3 ]
Stahl, James E. [2 ]
Schwartz, Joel H. [4 ]
Maloney, Betty [4 ]
Jacobson, Joseph O. [4 ]
机构
[1] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02215 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] N Shore Med Ctr, Salem, MA USA
[4] Mass General N Shore Canc Ctr, Peabody, MA USA
关键词
Chemotherapy; Adverse events; Cancer; Quality improvement; ADVERSE DRUG-REACTIONS; CLINICAL-TRIALS; ONCOLOGY PRACTICE; BREAST-CANCER; PARTICIPATION; QUALITY; ENROLLMENT; EVENTS; WOMEN; RACE;
D O I
10.1634/theoncologist.2010-0354
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. To describe the frequency, nature, trends, predictors, and outcomes of chemotherapy-related hospitalizations (CRHs) among a nonselected population of cancer patients treated at a community cancer center, and to explore the feasibility of implementing continuous quality improvement methodologies in routine oncology practice. Methods. We conducted a prospective cohort study of consecutive adult cancer patients who received chemo-therapy at a community cancer center January 2003 to December 2006. Demographic, comorbidity, diagnosis, treatment, and laboratory data were collected via medical record abstraction. Hospitalizations were classified as chemotherapy related or unrelated by a multidisciplinary panel. Patients who experienced CRHs were compared with those who did not. Using a randomly sampled subset of cases and controls, we built a logistic regression model to identify independent predictors of CRH. Results. Of 2,068 chemotherapy recipients, 179 (8.7%) experienced 262 CRHs. Most hospitalizations were not chemotherapy related (73.7%). The mean monthly rate of CRH was 1.5%, the median length of stay was 5 days, the most common type of CRH was gastrointestinal (46.1%) followed by infectious (31.4%), and 0.9% of chemotherapy recipients had a fatal CRH. Significant predictors of CRH included having a comorbidity score of 3-4 versus 0 and having a higher creatinine level. Conclusions. Although the vast majority of chemotherapy recipients did not experience a CRH, these events were, unfortunately, not without serious consequences. Care should be taken when offering chemotherapy to patients with multiple comorbid conditions. Systematic efforts to monitor toxicity can lead directly to improvements in quality of care. The Oncologist 2011;16:378-387
引用
收藏
页码:378 / 387
页数:10
相关论文
共 29 条
  • [1] Never too old?: Age should not be a barrier to enrollment in cancer clinical trials
    Aapro, MS
    Köhne, CH
    Cohen, HJ
    Extermann, M
    [J]. ONCOLOGIST, 2005, 10 (03) : 198 - 204
  • [2] Enrollment of African Americans onto clinical treatment trials: Study design barriers
    Adams-Campbell, LL
    Ahaghotu, C
    Gaskins, M
    Dawkins, FW
    Smoot, D
    Polk, OD
    Gooding, R
    Dewitty, RL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) : 730 - 734
  • [3] [Anonymous], American FactFinder
  • [4] SELECTION BIAS IN CLINICAL-TRIALS
    ANTMAN, K
    AMATO, D
    WOOD, W
    CORSON, J
    SUIT, H
    PROPPE, K
    CAREY, R
    GREENBERGER, J
    WILSON, R
    FREI, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (08) : 1142 - 1147
  • [5] Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center
    Blayney, Douglas W.
    McNiff, Kristen
    Hanauer, David
    Miela, Gretchen
    Markstrom, Denise
    Neuss, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3802 - 3807
  • [6] Britton A, 1999, J Health Serv Res Policy, V4, P112
  • [7] Exclusion of elderly people from clinical research: a descriptive study of published reports
    Bugeja, G
    Kumar, A
    Banerjee, AK
    [J]. BRITISH MEDICAL JOURNAL, 1997, 315 (7115) : 1059 - 1059
  • [8] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [9] Adverse drug reactions: definitions, diagnosis, and management
    Edwards, IR
    Aronson, JK
    [J]. LANCET, 2000, 356 (9237) : 1255 - 1259
  • [10] Generalizability of cancer clinical trial results
    Elting, LS
    Cooksley, C
    Bekele, BN
    Frumovitz, M
    Avritscher, EBC
    Sun, C
    Bodurka, DC
    [J]. CANCER, 2006, 106 (11) : 2452 - 2458